Olema Pharmaceuticals, Inc. (OLMA)
- Sector
- Biotechnology
- Last price
- $7.33
- As of
Kresmion compiles this page from OLMA's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Olema Pharmaceuticals, Inc. (OLMA): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-15.
See the full OLMA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for OLMA on one page. Preview it with sample data, then open it live with a free account.
Preview the OLMA dossierActive events for OLMA
- high13F: large reduction
CITADEL ADVISORS LLC cut 59% of OLMA (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +826% to OLMA (2026Q2)
- high13F: large reduction
Point72 Asset Management, L.P. cut 94% of OLMA (2026Q2)
- high13F: large increase
Point72 Asset Management, L.P. added +2674% to OLMA (2026Q2)
- mediumEarnings below estimates
Q2-2026: Missed consensus by 9.8%, EPS $-0.61 vs $-0.5554 estimate
FREE, NO ACCOUNT
Every event on OLMA, as it fires
You are seeing 5 of 13 events recorded on OLMA since 2026-05-26.
The five above landed across 2 days. The other 8 were recorded on 2 other days. 9 of the 13 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
OLMA positions held by the managers we follow (2026Q2)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| TWO SIGMA INVESTMENTS, LP FundCUSIP 68062P106 · 2026Q2 | $14.2M | 0.01% |
| Point72 Asset Management, L.P. FundCUSIP 68062P106 · 2026Q2 | $13.4M | 0.02% |
| CITADEL ADVISORS LLC FundCUSIP 68062P106 · 2026Q2 | $8M | 0.00% |
| D. E. Shaw & Co., Inc. FundCUSIP 68062P106 · 2026Q2 | $695K | 0.00% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, OLMA
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
Going concern statement
OLMA's 10-Q filed Aug 10, 2026 states:
As a result, these conditions raise substantial doubt about our ability to continue as a going concern over the long term.
Read the 10-Q on SEC EDGAR Every company with a going concern statement
More data on OLMA
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in OLMA on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on OLMA in the last 180 days.
Upstream: SEC EDGAR filings for OLMA
Kresmion, "Olema Pharmaceuticals, Inc. (OLMA) institutional holdings and SEC filings", data as of 2026-10-15, https://kresmion.com/research/OLMA. Upstream data: SEC EDGAR filings for OLMA.
Link to this data (HTML):
<a href="https://kresmion.com/research/OLMA">Olema Pharmaceuticals, Inc. (OLMA) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow OLMA on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to OLMA for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.